CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
40 EUR
-0.72 (-1.77%)
Overall AFX gets a fundamental rating of 5 out of 10. We evaluated AFX against 62 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AFX get a neutral evaluation. Nothing too spectacular is happening here. AFX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year AFX was profitable.
In the past year AFX had a positive cash flow from operations.
In the past 5 years AFX has always been profitable.
In the past 5 years AFX always reported a positive cash flow from operatings.
1.2 Ratios
AFX has a Return On Assets of 4.15%. This is in the better half of the industry: AFX outperforms 62.90% of its industry peers.
AFX has a Return On Equity (6.67%) which is in line with its industry peers.
Looking at the Return On Invested Capital, with a value of 5.79%, AFX is in line with its industry, outperforming 54.84% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AFX is below the industry average of 9.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
With a Profit Margin value of 6.34%, AFX perfoms like the industry average, outperforming 54.84% of the companies in the same industry.
In the last couple of years the Profit Margin of AFX has declined.
The Operating Margin of AFX (10.03%) is comparable to the rest of the industry.
AFX's Operating Margin has declined in the last couple of years.
AFX has a Gross Margin (52.76%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AFX is creating some value.
The number of shares outstanding for AFX remains at a similar level compared to 1 year ago.
AFX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for AFX has been reduced compared to a year ago.
2.2 Solvency
AFX has an Altman-Z score of 3.45. This indicates that AFX is financially healthy and has little risk of bankruptcy at the moment.
AFX has a Altman-Z score of 3.45. This is in the better half of the industry: AFX outperforms 64.52% of its industry peers.
The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.41, AFX is in line with its industry, outperforming 56.45% of the companies in the same industry.
A Debt/Equity ratio of 0.27 indicates that AFX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.27, AFX perfoms like the industry average, outperforming 59.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 3.45 |
ROIC/WACC0.86
WACC6.72%
2.3 Liquidity
A Current Ratio of 2.35 indicates that AFX has no problem at all paying its short term obligations.
AFX's Current ratio of 2.35 is fine compared to the rest of the industry. AFX outperforms 67.74% of its industry peers.
AFX has a Quick Ratio of 1.44. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
AFX has a better Quick ratio (1.44) than 70.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.90%.
AFX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
AFX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.82%.
Measured over the past years, AFX shows a quite strong growth in Revenue. The Revenue has been growing by 10.78% on average per year.
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
3.2 Future
AFX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.13% yearly.
The Revenue is expected to grow by 6.98% on average over the next years.
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y20.13%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.98%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
AFX is valuated rather expensively with a Price/Earnings ratio of 24.84.
69.35% of the companies in the same industry are more expensive than AFX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.51. AFX is around the same levels.
Based on the Price/Forward Earnings ratio of 19.96, the valuation of AFX can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 62.90% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of AFX to the average of the S&P500 Index (23.13), we can say AFX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.84 | ||
| Fwd PE | 19.96 |
4.2 Price Multiples
75.81% of the companies in the same industry are more expensive than AFX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AFX is valued a bit cheaper than the industry average as 69.35% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.85 | ||
| EV/EBITDA | 11.69 |
4.3 Compensation for Growth
AFX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AFX's earnings are expected to grow with 22.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.01
PEG (5Y)7.57
EPS Next 2Y22.06%
EPS Next 3Y22.65%
5. Dividend
5.1 Amount
AFX has a Yearly Dividend Yield of 1.36%.
Compared to an average industry Dividend Yield of 1.11, AFX pays a bit more dividend than its industry peers.
Compared to the average S&P500 Dividend Yield of 2.00, AFX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.36% |
5.2 History
The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
37.19% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
DP37.19%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
FRA:AFX (12/30/2025, 7:00:00 PM)
40
-0.72 (-1.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.58B
Revenue(TTM)2.23B
Net Income(TTM)141.22M
Analysts73.64
Price Target51.15 (27.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.36% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.94%
PT rev (3m)-7.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.17%
EPS NY rev (3m)-6.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.69%
Revenue NY rev (3m)-0.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.84 | ||
| Fwd PE | 19.96 | ||
| P/S | 1.61 | ||
| P/FCF | 26.85 | ||
| P/OCF | 17.05 | ||
| P/B | 1.69 | ||
| P/tB | 7.39 | ||
| EV/EBITDA | 11.69 |
EPS(TTM)1.61
EY4.03%
EPS(NY)2
Fwd EY5.01%
FCF(TTM)1.49
FCFY3.72%
OCF(TTM)2.35
OCFY5.87%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)1.01
PEG (5Y)7.57
Graham Number29.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 3.45 |
F-Score6
WACC6.72%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y20.13%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.98%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year66.85%
EBIT Next 3Y28.21%
EBIT Next 5Y23.57%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
What is the valuation status of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What are the PE and PB ratios of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 24.84 and the Price/Book (PB) ratio is 1.69.
Is the dividend of CARL ZEISS MEDITEC AG - BR sustainable?
The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 3 / 10 and the dividend payout ratio is 37.19%.